Schizophrenia Drugs Questioned

Join Our Community of Science Lovers!

Donald F. Klein of Columbia University remembers handing out the first pills for schizophrenia in 1955, when the only treatment was electroshock therapy. One patient, an institutionalized war veteran who had not spoken in decades, swallowed the medication and a few days later suddenly asked, “When am I getting out of this place?”

According to a new study, this early class of drugs may work just as well at reducing hallucinations and delusions as modern pills that cost up to 10 times more. In the early 1990s the new medications, such as Zyprexa and Seroquel, took over, promising greater effectiveness and less debilitating side effects, including tremors. The federal government sponsored the $43-million study as a check against the results of previous tests that had been sponsored by drug companies and as a way to evaluate Medicaid’s payout for high-priced schizophrenia medication, one of the program’s biggest expenses.

Overseen by Columbia’s director of psychiatry, Jeffrey A. Lieberman, the study randomly assigned one of five drugs—four from the new class, one from the old—to 1,460 chronically ill patients and followed them for 18 months. Lieberman’s team found that all five compounds were about equally effective. And at moderate doses, at least, adverse reactions from the old medication, Trilafon, were no worse than for the others.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Perhaps the biggest surprise, however, was that none of the pharmaceuticals satisfied patients. Almost 75 percent of the participants quit treatment, were taken out by their doctors or asked to be switched to another pill, because symptoms were not improving or side effects were intolerable. “We clearly need better drugs,” Lieberman says.

Although the old medications can cause tremors, stiffness and jerky muscle movements, the new medicines bring problems, too: weight gain and increased blood glucose, cholesterol and triglyceride levels, which put patients at risk for diabetes or heart disease. The rates of these side effects vary, so until better pills are actually devised, treatment may continue to be less than optimum.

SA Mind Vol 16 Issue 4This article was published with the title “Schizophrenia Drugs Questioned” in SA Mind Vol. 16 No. 4 (), p. 8
doi:10.1038/scientificamericanmind1205-8a

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe